Tonix Pharmaceuticals Receives Health Canada Clearance To Study A Novel Treatment For Fibromyalgia

Tonix Pharmaceuticals Holding Corp. (OTCBB: TNXP) (“TONIX” or the “Company”), a specialty pharmaceutical company developing therapies for challenging disorders of the central nervous system (“CNS”) including fibromyalgia syndrome (“FM”) and post-traumatic stress disorder (“PTSD”), announces that the Company will initiate a comparative study on a novel treatment for FM that targets sleep problems associated with chronic pain syndromes. TONIX’s new approach is opiate-free and non-addictive.

Health Canada has provided TONIX with clearance for a comparative pharmacokinetic (“PK”) and bioavailability (“BA”) study of TNX-102, the Company’s novel oral formulation of cyclobenzaprine for the treatment of FM. Health Canada has issued a No Objection Letter to TONIX’s Clinical Trial Application. Cyclobenzaprine is the active ingredient in two U.S. FDA- and Health Canada-approved prescription muscle relaxants that are marketed by other companies.

Seth Lederman, M.D., Chairman and President of TONIX said, “FM patients are desperate to get a good night’s sleep because many have learned that restorative sleep can improve their pain and fatigue. We have designed TNX-102 to work at night after bedtime administration. We expect the results of this PK study will corroborate studies done in animals, and we will use the findings to finalize our commercial formulation for pivotal clinical studies.”

Dr. Lederman also said, “The objective of this study is to compare the PK profile of our proprietary TNX-102 formulation with the PK of a conventional immediate release formulation and the PK of an intravenous injection.”

In addition, Dr. Lederman noted, “Immediate release cyclobenzaprine results in relatively steady blood levels over the course of the day, which is ideal for the treatment of muscle spasms, its approved indication. In our Phase 2a study, bedtime administration of very low dose cyclobenzaprine capsules improved core FM symptoms including pain, tenderness, fatigue and depression. This study also demonstrated that those improvements were correlated with increased nights of restorative sleep. Our goal is to develop a bedtime cyclobenzaprine treatment with more predictable beneficial effects and reduced next-day somnolence compared with the current doses and formulations of cyclobenzaprine.”

If you liked this article you might like

Mirati Skyrockets On Positive Data - Biotech Movers

5 Stocks Poised for Major Breakouts

Can You Catch These 6 Stocks Under $10 on Their Way Up?

6 Stocks Under $10 Making Big Moves Higher

Trade These 5 Breakout Stocks for Big Gains